Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms HELP
Based on 31,636 articles published since 2008
|||| 49 

These are the 31636 published articles about Pancreatic Neoplasms that originated from Worldwide during 2008-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
401 Editorial Strategy to differentiate autoimmune pancreatitis from pancreas cancer. 2012

Takuma, Kensuke / Kamisawa, Terumi / Gopalakrishna, Rajesh / Hara, Seiichi / Tabata, Taku / Inaba, Yoshihiko / Egawa, Naoto / Igarashi, Yoshinori. · ·World J Gastroenterol · Pubmed #22416175.

ABSTRACT: Autoimmune pancreatitis (AIP) is a newly described entity of pancreatitis in which the pathogenesis appears to involve autoimmune mechanisms. Based on histological and immunohistochemical examinations of various organs of AIP patients, AIP appears to be a pancreatic lesion reflecting a systemic "IgG4-related sclerosing disease". Clinically, AIP patients and patients with pancreatic cancer share many features, such as preponderance of elderly males, frequent initial symptom of painless jaundice, development of new-onset diabetes mellitus, and elevated levels of serum tumor markers. It is of uppermost importance not to misdiagnose AIP as pancreatic cancer. Since there is currently no diagnostic serological marker for AIP, and approach to the pancreas for histological examination is generally difficult, AIP is diagnosed using a combination of clinical, serological, morphological, and histopathological features. Findings suggesting AIP rather than pancreatic cancer include: fluctuating obstructive jaundice; elevated serum IgG4 levels; diffuse enlargement of the pancreas; delayed enhancement of the enlarged pancreas and presence of a capsule-like rim on dynamic computed tomography; low apparent diffusion coefficient values on diffusion-weighted magnetic resonance image; irregular narrowing of the main pancreatic duct on endoscopic retrograde cholangiopancreatography; less upstream dilatation of the main pancreatic duct on magnetic resonance cholangiopancreatography, presence of other organ involvement such as bilateral salivary gland swelling, retroperitoneal fibrosis and hilar or intrahepatic sclerosing cholangitis; negative work-up for malignancy including endoscopic ultrasound-guided fine needle aspiration; and steroid responsiveness. Since AIP responds dramatically to steroid therapy, accurate diagnosis of AIP can avoid unnecessary laparotomy or pancreatic resection.

402 Editorial [Pancreatic tumor: progress in diagnosis and treatment. Editorial: trend of clinical management of pancreatic tumors]. 2012

Shimosegawa, Tooru. · ·Nihon Naika Gakkai Zasshi · Pubmed #22413454.

ABSTRACT: -- No abstract --

403 Editorial Revising you the staging for pancreatic cancer in 2012. 2012

Saif, Muhammad Wasif. · ·JOP · Pubmed #22406582.

ABSTRACT: -- No abstract --

404 Editorial Pancreatic neoplasm in 2012: an update. Tissue is an issue! 2012

Saif, Muhammad Wasif. · ·JOP · Pubmed #22406581.

ABSTRACT: -- No abstract --

405 Editorial Targeting opioidergic pathways as a novel biological treatment for advanced pancreatic cancer. 2012

Zagon, Ian S / McLaughlin, Patricia J. · ·Expert Rev Gastroenterol Hepatol · Pubmed #22375517.

ABSTRACT: -- No abstract --

406 Editorial Cystic lesions of the pancreas: more reliable differentiation with in situ high-resolution optical imaging? 2012

Iftimia, Nicusor / Yoon, Won Jae / Brugge, William R. · ·Expert Rev Gastroenterol Hepatol · Pubmed #22375515.

ABSTRACT: -- No abstract --

407 Editorial Targeted therapies for pancreatic cancer. 2012

Ma, Qingyong. · ·Curr Pharm Des · Pubmed #22372496.

ABSTRACT: -- No abstract --

408 Editorial The promise and perils of measuring circulating tumor cells. 2012

Markman, Maurie. · ·Oncology · Pubmed #22270101.

ABSTRACT: -- No abstract --

409 Editorial Intraductal papillary mucinous neoplasms of the biliary and pancreatic ducts--a shape shifting outlook into an increasingly recognized disease. 2012

Crippa, Stefano / Falconi, Massimo. · ·Dig Liver Dis · Pubmed #22265327.

ABSTRACT: -- No abstract --

410 Editorial The prognosis for pancreatic cancer patients--better than feared. 2012

Buanes, Trond. · ·Tidsskr Nor Laegeforen · Pubmed #22240836.

ABSTRACT: -- No abstract --

411 Editorial What can we learn from Steve Jobs about complementary and alternative therapies? 2012

Greenlee, Heather / Ernst, Edzard. · ·Prev Med · Pubmed #22230682.

ABSTRACT: -- No abstract --

412 Editorial 18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster? 2012

Boerman, Otto C / Gotthardt, Martin. · ·Eur J Nucl Med Mol Imaging · Pubmed #22170323.

ABSTRACT: -- No abstract --

413 Editorial Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. 2012

Koido, Shigeo / Homma, Sadamu / Takahara, Akitaka / Namiki, Yoshihisa / Komita, Hideo / Uchiyama, Kan / Ito, Masaki / Gong, Jianlin / Ohkusa, Toshifumi / Tajiri, Hisao. · ·Immunotherapy · Pubmed #22149993.

ABSTRACT: -- No abstract --

414 Editorial Pancreatic cancer is not noble. 2012

Lotze, Michael T. · ·J Innate Immun · Pubmed #22086192.

ABSTRACT: -- No abstract --

415 Editorial Proteome-based biomarkers in pancreatic cancer. 2011

Sun, Chen / Rosendahl, Ann H / Ansari, Daniel / Andersson, Roland. · ·World J Gastroenterol · Pubmed #22171124.

ABSTRACT: Pancreatic cancer, as a highly malignant cancer and the fourth cause of cancer-related death in world, is characterized by dismal prognosis, due to rapid disease progression, highly invasive tumour phenotype, and resistance to chemotherapy. Despite significant advances in treatment of the disease during the past decade, the survival rate is little improved. A contributory factor to the poor outcome is the lack of appropriate sensitive and specific biomarkers for early diagnosis. Furthermore, biomarkers for targeting, directing and assessing therapeutic intervention, as well as for detection of residual or recurrent cancer are also needed. Thus, the identification of adequate biomarkers in pancreatic cancer is of extreme importance. Recently, accompanying the development of proteomic technology and devices, more and more potential biomarkers have appeared and are being reported. In this review, we provide an overview of the role of proteome-based biomarkers in pancreatic cancer, including tissue, serum, juice, urine and cell lines. We also discuss the possible mechanism and prospects in the future. That information hopefully might be helpful for further research in the field.

416 Editorial Pancreatic metastases from renal cell carcinoma: the state of the art. 2011

Ballarin, Roberto / Spaggiari, Mario / Cautero, Nicola / De Ruvo, Nicola / Montalti, Roberto / Longo, Cristina / Pecchi, Anna / Giacobazzi, Patrizia / De Marco, Giuseppina / D'Amico, Giuseppe / Gerunda, Giorgio Enrico / Di Benedetto, Fabrizio. · ·World J Gastroenterol · Pubmed #22147975.

ABSTRACT: Pancreatic metastases are rare, with a reported incidence varying from 1.6% to 11% in autopsy studies of patients with advanced malignancy. In clinical series, the frequency of pancreatic metastases ranges from 2% to 5% of all pancreatic malignant tumors. However, the pancreas is an elective site for metastases from carcinoma of the kidney and this peculiarity has been reported by several studies. The epidemiology, clinical presentation, and treatment of pancreatic metastases from renal cell carcinoma are known from single-institution case reports and literature reviews. There is currently very limited experience with the surgical resection of isolated pancreatic metastasis, and the role of surgery in the management of these patients has not been clearly defined. In fact, for many years pancreatic resections were associated with high rates of morbidity and mortality, and metastatic disease to the pancreas was considered to be a terminal-stage condition. More recently, a significant reduction in the operative risk following major pancreatic surgery has been demonstrated, thus extending the indication for these operations to patients with metastatic disease.

417 Editorial Targeting thrombosis in exocrine pancreas cancer: a continued need for improved therapies. 2011

Epstein, Andrew S / O'Reilly, Eileen M. · ·Expert Rev Anticancer Ther · Pubmed #22117145.

ABSTRACT: -- No abstract --

418 Editorial ¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases. 2011

Nguyen, Vien X / Nguyen, Cuong C / Nguyen, Ba D. ·Department of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA. vnguy01@gmail.com ·JOP · Pubmed #22072244.

ABSTRACT: Since the introduction of integrated positron emission tomography-computed tomography (PET/CT), it has a great impact on the field of oncology. Comparing to other conventional scanners, only PET/CT is capable of providing important information on accurate detecting, staging/restaging, and post-therapeutic monitoring of many cancers. Many studies have demonstrated that PET/CT changes the management in approximately 30% of all cancer patients. Because 2-((18)F)-fluoro-2-deoxy-D-glucose (FDG) is a nonspecific tracer, understanding the PET/CT limitations and pitfalls for various pancreatic conditions can lead to more accurate interpretation of PET/CT images, which ultimately would impact patient care. As a result, it is important for radiologists and other clinicians to familiarize themselves with a wide spectrum of pancreatic PET/CT findings simulating cancer from benign entities.

419 Editorial Better imaging versus better value: striking a balance in confocal laser endomicroscopy. 2011

Hernandez, Lyndon V. · ·Gastrointest Endosc · Pubmed #22032313.

ABSTRACT: -- No abstract --

420 Editorial Outcomes when cancer treatment is delivered on, or off, a clinical trial: implications for generalizability of study results. 2011

Markman, Maurie. · ·Oncology · Pubmed #22024941.

ABSTRACT: -- No abstract --

421 Editorial What's new in oncologic pancreatic surgery. 2011

Ziparo, V / La Torre, M. · ·G Chir · Pubmed #22018213.

ABSTRACT: -- No abstract --

422 Editorial Locally advanced pancreatic cancer: where should we go from here? 2011

Philip, Philip Agop. · ·J Clin Oncol · Pubmed #21969514.

ABSTRACT: -- No abstract --

423 Editorial Significance of pathologic response to preoperative therapy in pancreatic cancer: the future ain't what it used to be. 2011

Allen, Peter J. · ·Ann Surg Oncol · Pubmed #21947699.

ABSTRACT: -- No abstract --

424 Editorial Pancreatic cancer in the UK. 2011

Anonymous3190705. · ·Lancet · Pubmed #21924981.

ABSTRACT: -- No abstract --

425 Editorial Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. 2011

Liakakos, Theodore / Roukos, Dimitrios H. · ·Future Oncol · Pubmed #21919689.

ABSTRACT: -- No abstract --

Back · Next